Online inquiry

IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12139MR)

This product GTTS-WQ12139MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD248 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_020404.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57124
UniProt ID Q9HCU0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ12139MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7533MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GC-182
GTTS-WQ5147MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ7582MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA G-CSF
GTTS-WQ9760MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ2029MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ14164MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ3614MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ797MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Ab-2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW